Drug Trial Radar · NCT06116136
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Actual
Start
Aug 31, 2024
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Servier Bio-Innovation LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC; Institut de Recherches Internationales Servier
- First posted
- Nov 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.
Conditions
- MSI-H/dMMR Gastroesophageal-junction Cancer
- MSI-H/dMMR Gastric Cancer
Interventions
S095029Drug
Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W).
pembrolizumab 200 mg (KEYTRUDA ®)Drug
Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Dose-Limiting Toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Total Number of Adverse Events (AEs)Time frame: From screening to 90 days after the last dose
- Adverse Events (AEs) Leading to Dose Interruption, Modification, or DelaysTime frame: From screening to 90 days after the last dose
- Adverse Events (AEs) Leading to Dose DiscontinuationTime frame: From screening to 90 days after the last dose
- Objective Response Rate (ORR)Time frame: Approximately 2 years
Locations
49 sites in 15 countries. Site status is shown where the registry gives one.
Ocala Oncology Center Pl
Ocala, Florida
Investigative Clinical Research of Indiana, Llc
Noblesville, Indiana
MD Anderson Cancer Center
Houston, Texas
The Queen Elizabeth Hospital
Woodville South, Australia
Landeskrankenhaus (SALK)
Salzburg, Austria
Med Universitat Wien-Allgemeines Krankenhaus Der Stadt Wien (AKH)
Vienna, State of Vienna, Austria
Ordensklinikum Linz
Linz, Upper Austria, Austria
UZ Leuven Campus Gasthuisberg
Leuven, Belgium
Chu de Liege
Liège, Belgium
Cepon - Centro de Pesquisas Oncologicas
Florianópolis, Brazil
Supera Oncologia
Santa Catarina, Brazil
Icesp - Instituto Do Câncer Do Estado de São Paulo
São Paulo, Brazil
Instituto Brasileiro de Controle Do Câncer
São Paulo, Brazil
Hospital Albert Einstein
São Paulo, Brazil
Mount Sinai Hospital
Toronto, Canada
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
Shandong Cancer Hospital Institute
Jinan, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine Qingchun Branch
Hangzhou, Zhengjiang Province, China
Rigshospitalet
Copenhagen, Denmark
Odense Universitetshospital
Odense, Denmark
Institut Bergonié
Bordeaux, France
Centre Georges Francois Leclerc
Dijon, France
Chru Lille - Hopital Claude Huriez
Lille, France
Institut Curie
Saint-Cloud, France
Inst. de Cancer de L'ouest
Saint-Herblain, France
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, France
Semmelweis Egyetem
Budapest, Hungary
Orszagos Onkologiai Intezet
Budapest, Hungary
Bugat Pal Hospital
Gyöngyös, Hungary
Bekes Megyei Kozponti Korhaz
Gyula, Hungary
A.O.U. Seconda Università Degli Studi Di Napoli
Campania, Italy
Fondazione IRCCS Istituto Nazionale dei Tumor
Milan, Italy
A.O.U. Pisana-Ospedale Santa Chiara
Pisa, Italy
Policlinico Universitario Agostino Gemelli
Rome, Italy
Policlinico G.B. Rossi A.O.U.I. Di Verona
Verona, Italy
National Cancer Center Hospital
Chou-ku, Japan
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.